| |
| |
|
| Insider
Information: |
Baker Julian |
| Relationship: |
|
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
33 |
|
| Direct
Shares |
1,028,565 |
|
|
Indirect Shares
|
243,774,473 |
|
|
| Direct
Value |
$73,841,312 |
|
|
|
Indirect Value
|
$16,621,918,985 |
|
|
| Total
Shares |
244,803,038 |
|
|
| Total
Value |
$16,695,760,297 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
46
|
7
|
|
Stock
price went up :
|
23
|
7
|
| Stock
price went down : |
23
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
7.0
|
| Percentage
Gain/Loss : |
 11.8%
|
80.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Synageva BioPharma Corp |
GEVA |
10% Owner |
2003-09-26 |
0 |
2011-11-02 |
144,082 |
Premium* |
|
|
Innoviva Inc |
INVA |
Director |
2005-12-13 |
0 |
2004-10-04 |
33,839 |
Premium* |
|
|
Ardea Biosciences Inc |
RDEA |
Director, 10% Owner |
2004-10-13 |
0 |
2011-06-30 |
4,045,398 |
Premium* |
|
|
Incyte Corp |
INCY |
|
2024-05-07 |
559,963 |
2024-05-07 |
33,496,391 |
Premium* |
|
|
Genomic Health Inc |
GHDX |
Director, 10% Owner |
2019-08-29 |
0 |
2019-08-29 |
9,262,659 |
Premium* |
|
|
Allos Therapeutics Inc |
ALTH |
10% Owner |
2009-01-23 |
0 |
2009-01-23 |
2,258 |
Premium* |
|
|
Viropharma Inc |
VPHM |
10% Owner |
|
0 |
2011-12-14 |
9,840,469 |
Premium* |
|
|
Heron Therapeutics Inc |
HRTX |
10% Owner |
|
0 |
2009-10-19 |
5,264,782 |
Premium* |
|
|
Diadexus Inc |
DDXS |
10% Owner |
|
0 |
2012-01-27 |
0 |
Premium* |
|
|
Pharmacyclics Inc |
PCYC |
10% Owner |
2011-08-22 |
0 |
2012-02-10 |
557,211 |
Premium* |
|
|
XOMA Corporation |
XOMA |
Former 10% owner |
|
0 |
2015-07-22 |
90,538 |
Premium* |
|
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2012-03-12 |
0 |
2012-03-14 |
3,540,015 |
Premium* |
|
|
Neurogene |
NGNE |
Director |
2020-07-07 |
4,520 |
2020-07-07 |
3,501,691 |
Premium* |
|
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2021-06-22 |
205,752 |
2021-06-22 |
38,452,877 |
Premium* |
|
|
Invitae Corp |
NVTA |
10% Owner |
2018-03-28 |
0 |
2018-03-28 |
7,553,553 |
Premium* |
|
|
Aceragen, Inc |
ACGN |
10% Owner |
2019-07-01 |
43,858 |
2019-07-01 |
4,290,995 |
Premium* |
|
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
Former 10% owner |
2017-10-05 |
0 |
2017-10-05 |
1,878,242 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
10% Owner |
2017-11-08 |
274 |
2017-11-08 |
35,999 |
Premium* |
|
|
Bellicum Pharmaceuticals, Inc |
BLCM |
10% Owner |
2018-01-17 |
0 |
2018-01-19 |
58,131 |
Premium* |
|
|
Beigene Ltd |
BGNE |
Director, 10% Owner |
2021-06-16 |
20,838 |
2021-06-16 |
11,703,086 |
Premium* |
|
|
Seagen Inc |
SGEN |
Director, 10% Owner |
2021-05-14 |
46,557 |
2021-05-14 |
43,309,073 |
Premium* |
|
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2020-05-14 |
131,963 |
2020-05-14 |
7,940,623 |
Premium* |
|
|
Kiniksa Pharmaceuticals, Ltd. |
KNSA |
Director, 10% Owner |
2019-06-06 |
14,840 |
2019-06-06 |
2,700,597 |
Premium* |
|
|
Kodiak Sciences Inc. |
KOD |
Director, 10% Owner |
2018-10-09 |
0 |
2021-09-30 |
13,526,726 |
Premium* |
|
|
Atreca Inc |
BCEL |
10% Owner |
2019-06-24 |
0 |
2019-06-24 |
3,223,030 |
Premium* |
|
|
Igm Biosciences, Inc. |
IGMS |
Director, 10% Owner |
2019-09-20 |
0 |
2021-01-27 |
2,895,306 |
Premium* |
|
|
Prelude Therapeutics Inc |
PRLD |
Director, 10% Owner |
|
0 |
2021-01-27 |
9,252,951 |
Premium* |
|
|
DBV Technologies SA |
DBVT |
Director, 10% Owner |
|
0 |
2021-01-01 |
4,286,038 |
Premium* |
|
|
Talis Biomedical Corp |
TLIS |
Director, 10% Owner |
|
0 |
2021-02-17 |
7,003,766 |
Premium* |
|
|
Aeglea Biotherapeutics, Inc. |
AGLE |
Director |
|
0 |
2021-02-23 |
3,410,106 |
Premium* |
|
|
Tscan Therapeutics, Inc. |
TCRX |
Director |
2021-07-20 |
0 |
2021-07-20 |
1,320,302 |
Premium* |
|
|
Entrada Therapeutics, Inc. |
TRDA |
10% Owner |
|
0 |
2021-12-14 |
4,704,419 |
Premium* |
|
|
Bicycle Therapeutics Ltd |
BCYC |
|
|
0 |
2024-04-18 |
6,449,320 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
496 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 18 of 20
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGEN |
Seagen Inc |
Director |
– • • |
2020-05-07 |
4 |
S |
$163.41 |
$27,660,947 |
I/I |
(168,244) |
45,348,951 |
0 |
% |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2020-05-08 |
4 |
S |
$158.50 |
$79,250,000 |
I/I |
(500,000) |
44,891,148 |
0 |
% |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2020-05-14 |
4 |
A |
$0.00 |
$0 |
I/I |
9,314 |
7,846,213 |
0 |
- |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2020-05-15 |
4 |
S |
$160.00 |
$280,000,000 |
I/I |
(1,750,000) |
43,288,836 |
0 |
% |
|
| SGEN |
Seagen Inc |
Director |
– • • |
2020-05-15 |
4 |
A |
$0.00 |
$0 |
I/I |
2,670 |
43,290,171 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2020-05-26 |
4 |
A |
$0.00 |
$0 |
I/I |
2,564 |
29,313,197 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2020-05-28 |
4 |
B |
$102.55 |
$205 |
I/I |
2 |
29,313,198 |
2.17 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2020-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
12,236 |
38,440,095 |
0 |
- |
|
| INCY |
Incyte Corp |
Director |
– • • |
2020-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
588 |
29,313,492 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • • |
2020-07-01 |
4 |
A |
$0.00 |
$0 |
I/I |
446 |
2,883,650 |
0 |
- |
|
| NGNE |
Neurogene |
Director |
– • – |
2020-07-07 |
4 |
B |
$15.25 |
$6,466,000 |
I/I |
424,000 |
3,501,691 |
2.1 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • • |
2020-07-15 |
4 |
A |
$14.23 |
$207,544,549 |
I/I |
14,584,180 |
18,840,379 |
0 |
- |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-08-19 |
4 |
B |
$46.99 |
$181,791 |
I/I |
3,869 |
10,606,135 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-08-20 |
4 |
B |
$46.30 |
$2,871,156 |
I/I |
60,573 |
10,662,260 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-08-21 |
4 |
B |
$47.74 |
$6,762,056 |
I/I |
139,044 |
10,791,092 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-09-03 |
4 |
B |
$46.97 |
$5,942,904 |
I/I |
123,883 |
10,905,982 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-09-04 |
4 |
B |
$45.30 |
$3,869,473 |
I/I |
82,801 |
10,982,772 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-09-08 |
4 |
B |
$45.88 |
$5,505,934 |
I/I |
116,295 |
11,090,409 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-09-22 |
4 |
B |
$49.72 |
$3,797,911 |
I/I |
74,958 |
11,160,400 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-09-23 |
4 |
B |
$51.97 |
$4,826,756 |
I/I |
92,069 |
11,246,368 |
2.25 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-09-24 |
4 |
B |
$51.41 |
$1,873,924 |
I/I |
36,020 |
11,280,001 |
2.25 |
% |
|
| PRLD |
Prelude Therapeutics Inc |
Director |
– • • |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
206,911 |
|
- |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • • |
2020-09-25 |
4 |
B |
$55.35 |
$2,726,182 |
I/I |
48,125 |
11,324,937 |
2.25 |
% |
|
| PRLD |
Prelude Therapeutics Inc |
Director |
– • • |
2020-09-29 |
4 |
B |
$19.00 |
$29,999,993 |
I/I |
1,578,947 |
9,247,763 |
2.25 |
- |
|
| PRLD |
Prelude Therapeutics Inc |
Director |
– • • |
2020-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
8,332,778 |
7,773,444 |
0 |
- |
|
496 Records found
|
|
Page 18 of 20 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
